BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

14 related articles for article (PubMed ID: 38506035)

  • 1. Circ_0003998 enhances doxorubicin resistance in hepatocellular carcinoma by regulating miR-218-5p/EIF5A2 pathway.
    Li X; He J; Ren X; Zhao H; Zhao H
    Diagn Pathol; 2020 Dec; 15(1):141. PubMed ID: 33308276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-33a-5p overexpression sensitizes triple-negative breast cancer to doxorubicin by inhibiting eIF5A2 and epithelial-mesenchymal transition.
    Guan X; Gu S; Yuan M; Zheng X; Wu J
    Oncol Lett; 2019 Dec; 18(6):5986-5994. PubMed ID: 31788073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2.
    Tu C; Chen W; Wang S; Tan W; Guo J; Shao C; Wang W
    J Cell Mol Med; 2019 Nov; 23(11):7190-7199. PubMed ID: 30801960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of miR-15a-5p Promotes the Chemoresistance to Pirarubicin in Hepatocellular Carcinoma via Targeting eIF4E.
    Zhang Y; Tie Q; Bao Z; Shao Z; Zhang L
    Comput Math Methods Med; 2021; 2021():6468405. PubMed ID: 34812269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N1-guanyl-1,7-diaminoheptane sensitizes bladder cancer cells to doxorubicin by preventing epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2 activation.
    Yang J; Yu H; Shen M; Wei W; Xia L; Zhao P
    Cancer Sci; 2014 Feb; 105(2):219-27. PubMed ID: 24262005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. microRNA-15a-5p suppresses hypoxia-induced tumor growth and chemoresistance in bladder cancer by binding to eIF5A2.
    Yang J; Xiang H; Cheng M; Jiang X; Chen Y; Zheng L; Yan S; Zhang S; Zhang C; Chen W; Chen D
    Neoplasma; 2024 Feb; 71(1):60-69. PubMed ID: 38506035
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 8.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 9.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 10.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 1.